# Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

> PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-28003770-afamelanotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28003770-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28003770-afamelanotide-v1.json
- Content SHA-256: `cfaff22e9b8b9c8305a8608dd89d20e8bac1bcff2ae55f5a3336891207b49996`

## Claims and source pins

### Headline

Advances in the management of erythropoietic protoporphyria - role of afamelanotide. ([`pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf`](#source-pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf))

### Summary

PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf`](#source-pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf))

### Paragraph 1

PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf`](#source-pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf`](#source-pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf))

## Sources

<a id="source-pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf"></a>
- **Advances in the management of erythropoietic protoporphyria - role of afamelanotide. · retained source version 1:2023-11-11:current:afc0bd25e3bfe0c83a9a98a61df1bf5d5581e57a7b0fe39d6123ae61744ffbc5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28003770/) (`pubmed-observation-pmid-28003770-2023-11-11-afc0bd25e3bf`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Advances in the management of erythropoietic protoporphyria - role of afamelanotide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-28003770-afamelanotide-v1.json SHA-256: cfaff22e9b8b9c8305a8608dd89d20e8bac1bcff2ae55f5a3336891207b49996.